As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Huapont Life Sciences has three main business lines, including pharmaceuticals, pesticides, and active pharmaceutical ingredients (APIs). The company manufactures dermatology, tuberculosis, and cancer treatment drugs. Its pesticide business involves the production and sale of herbicides, including NC36, NC125, NC201, NC34, and NC16. Its API business centers on supplying bulk pharmaceutical chemicals, intermediates, and preparing Chinese and Western medicines.
In August 2014, Huapont Life Sciences invested $220 million for a 15% stake in Albaugh, one of the largest generic agro-chemical manufacturers in the United States. In July 2016, Huapont Life Sciences entered into an equity and license agreement with Angionetics, a cardiovascular firm in California, investing $3 million for 15% of preferred stock. The investment will support the clinical development of a heart disease therapy.
In December 2015, Huapont acquired a 69.84% stake in Swiss Biological Medicine company for $30.4 million.